juvenile arthritis

临床试验

计划入组 140 人 · 首次发布于 2025 年 10 月 16 日

招募中

NCT02684695

Juvenile Arthritis Quantitative Imaging

计划入组 200 人 · 首次发布于 2016 年 2 月 18 日

已完成

NCT01166750

Jointstrong Intervention for Juvenile Arthritis

计划入组 35 人 · 首次发布于 2010 年 7 月 21 日

药物

查看全部 116 →

Small Molecule

Approved

Oxaprozin(Coxanto, Daypro)

生产企业：Gd searle llc, Actavis elizabeth llc，另有 9 家

相关疾病：Osteoarthritis (OA), Rheumatoid Arthritis，另有 1 项

C₁₈H₁₅NO₃

Small Molecule

Approved

Tolmetin

生产企业：Ortho mcneil janssen pharmaceuticals inc, Actavis elizabeth llc，另有 5 家

相关疾病：Ankylosing Spondylitis (AS), Osteoarthritis (OA)，另有 2 项

C₁₅H₁₅NO₃

Small Molecule

Approved

Meloxicam(Anjeso, Mobic, Qmiiz, Vivlodex)

生产企业：Boehringer ingelheim pharmaceuticals inc, Actavis totowa llc，另有 21 家

相关疾病：Dental Pain, Neuropathic Pain，另有 6 项

C₁₄H₁₃N₃O₄S₂ · Rx

机构

查看全部 16 →

CARE Arthritis Ltd

Canada

Arthritis Innovation Corporation

Canada

The Stone Research Foundation For Sports Medicine and Arthritis

United States

资讯

查看全部 902 →

去年

FDA Expands Jylamvo Approval to Include Polyarticular Juvenile Idiopathic Arthritis and ALL

去年

FDA Grants Rare Pediatric Disease Designation to 101-PGC-005 for Systemic Juvenile Idiopathic Arthritis

去年

临床试验

Pain in Juvenile Arthritis

Juvenile Arthritis Quantitative Imaging

Jointstrong Intervention for Juvenile Arthritis

药物

Oxaprozin(Coxanto, Daypro)

Tolmetin

Meloxicam(Anjeso, Mobic, Qmiiz, Vivlodex)

机构

CARE Arthritis Ltd

Arthritis Innovation Corporation

The Stone Research Foundation For Sports Medicine and Arthritis

资讯

FDA Expands Jylamvo Approval to Include Polyarticular Juvenile Idiopathic Arthritis and ALL

FDA Grants Rare Pediatric Disease Designation to 101-PGC-005 for Systemic Juvenile Idiopathic Arthritis

FDA Expands Methotrexate Approval for Pediatric ALL and Juvenile Idiopathic Arthritis